---
title: Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
nct_id: NCT05264753
overall_status: RECRUITING
sponsor: Occlutech International AB
study_type: OBSERVATIONAL
primary_condition: Patent Ductus Arteriosus
countries: Canada, France, Ireland, Italy, Pakistan, Sweden, Switzerland, Tunisia, Turkey (Türkiye), United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05264753.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05264753"
ct_last_update_post_date: 2026-01-27
last_seen_at: "2026-05-12T07:11:19.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

**Official Title:** A Multicenter, International, Prospective, Retrospective, Post Marketing Clinical Follow Up Study to Evaluate the Efficacy and Safety of the Occlutech Patent Ductus Arteriosus Occluder (PDA Occluder) in Patients With Patent Ductus Arteriosus Defects

**NCT ID:** [NCT05264753](https://clinicaltrials.gov/study/NCT05264753)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 255
- **Lead Sponsor:** Occlutech International AB
- **Conditions:** Patent Ductus Arteriosus
- **Start Date:** 2021-12-20
- **Completion Date:** 2029-11-25
- **CT.gov Last Update:** 2026-01-27

## Brief Summary

This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects with patent ductus arteriosus (PDA) defects. Safety and efficacy assessments include vital signs, electrocardiograms, and echocardiographic evaluations performed at baseline/implantation (including assessments within 36 hours post procedure), as well as at follow up visits occurring between Day 30 and Day 90, 6 months to 1 year, 1 to 2 years, and 2 to 3 years after implantation.

## Detailed Description

The Occlutech® PDA Occluder is an occlusion system designed for the percutaneous, catheter based, non surgical closure of Patent Ductus Arteriosus (PDA), and is delivered using the Occlutech Occlusions Pusher (OOP) and Occlutech Delivery Set (ODS), which are recommended as compatible delivery systems. This post marketing clinical follow up study aims to evaluate the safety and efficacy of the Occlutech® PDA Occluder in subjects with PDA. The study is designed as a retrospective and prospective, multicenter, international investigation in which safety and efficacy will be assessed through vital signs, electrocardiography, and echocardiography at baseline/implantation (including assessments performed within 36 hours post procedure), followed by evaluations at Day 30 to Day 90, 6 months to 1 year, 1 to 2 years, and 2 to 3 years after implantation. A total of 217 evaluable subjects is required to estimate a proportion of ≤10% (or ≥90%) with a precision of 4% at an alpha level of 5%, corresponding to a two sided 95% confidence interval width of ≤8%. To account for an anticipated maximum drop out rate of 15%, a total of 255 subjects will be enrolled. Approximately 90% of enrolled participants are expected to be children aged 0-10 years. The primary objective of this study is to assess the safety of the Occlutech® PDA Occluder in subjects requiring transcatheter PDA closure, while the secondary objective is to evaluate the device's efficacy in achieving successful occlusion of the PDA

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* A subject of any age will be eligible for PDA closure if he or she meets the indication and area of application as laid down in the IFU. Including subjects more than 3 kg. Thus, the Occlutech PDA Occluder is intended for the non-surgical occlusion of Patent Ductus Arteriosus (PDA) defects.
* Male or female subjects.
* Subjects or their parents/guardians understanding the nature of the study and providing their informed consent to participation.
* Subjects willing and able to attend the follow-up visits and procedures foreseen by study CIP.

Exclusion Criteria:

Contraindications as laid down in the IFU:

* Silent ductus or serious pulmonary hypertension:
* Pulmonary Vascular Resistance (PVR) \> 8 Wood Units
* Presence of a known coagulation disorder
* Thrombus at the position allocated for the implantation
* A vein thrombosis in the blood vessels chosen for the introducing system
* An active infection (active endocarditis or other infections causing bacteremia) or history of endocarditis within 3 months from the procedure.
* Nitinol intolerance (nickel or titanium)
* Contrast medium intolerance
* Subjects who have a vascular system (which is used to access the defect) that is too small to admit the required sheath
```

## Interventions

- **Occlutech® PDA Occluder** (DEVICE) — Non-surgical occlusion of Patent Ductus Arteriosus (PDA).

## Primary Outcomes

- **Safety primary endpoint** _(time frame: 1 year)_ — The primary safety endpoint is defined as the incidence of any Serious Adverse Device Effects (SADEs) including procedure-related death, procedure-related stroke, systemic embolism, severe hemolysis, device embolization, cardiac tamponade, infective endocarditis, or vascular complications requiring surgery up to 1-year post-implantation.
- **Efficacy primary endpoint** _(time frame: 2 years)_ — The primary efficacy endpoint is defined as successful implantation of the Occlutech® PDA Occluder with a complete closure of the PDA (defined as \>90% PDA closure represented by no or small residual flow) as assessed by echocardiography post-implantation) within 2-year post- implantation follow-up.

## Secondary Outcomes

- **Safety secondary endpoint** _(time frame: 3 years)_
- **Efficacy secondary endpoint** _(time frame: 3 years)_

## Locations (15)

- CHU Sainte-Justine, Montreal, Canada — _NOT_YET_RECRUITING_
- CHU de Lille - Institut Cœur-Poumon, Lille, France — _NOT_YET_RECRUITING_
- Hôpital Mère Enfant, CHU de Nantes, Nantes, France — _RECRUITING_
- Children's Hospital Ireland at Crumlin, Dublin, Ireland — _NOT_YET_RECRUITING_
- Ospedale Pediatrico Bambino Gesù, Roma, Roma, Italy — _RECRUITING_
- Rawalpindi Institute of Cardiology, Rawalpindi, Rawalpindi, Pakistan — _RECRUITING_
- Children´s Hospital, Karolinska University, Stockholm, Sweden — _NOT_YET_RECRUITING_
- Insel Gruppe, Bern, Switzerland — _NOT_YET_RECRUITING_
- Hospital La Rabta, Tunis, Tunisia — _RECRUITING_
- Military Hospital, Tunis, Tunisia — _RECRUITING_
- Aydın Adnan Menderes University Hospital, Aydin, Efeler, Turkey (Türkiye) — _RECRUITING_
- Eskişehir Osmangazi University Hospital, Eskişehir, Eskişehir, Turkey (Türkiye) — _RECRUITING_
- Çukurova University Hospital, Adana, Sarıçam, Turkey (Türkiye) — _RECRUITING_
- Dicle University Hospital, Diyarbakır, SUR, Turkey (Türkiye) — _RECRUITING_
- Royal Brompton & Harefield Hospitals, London, London, United Kingdom — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `locations.children's hospital ireland at crumlin|dublin||ireland` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu sainte-justine|montreal||canada` — added _(2026-05-12)_
- `locations.chu de lille - institut cœur-poumon|lille||france` — added _(2026-05-12)_
- `locations.hôpital mère enfant, chu de nantes|nantes||france` — added _(2026-05-12)_
- `locations.ospedale pediatrico bambino gesù|roma|roma|italy` — added _(2026-05-12)_
- `locations.rawalpindi institute of cardiology|rawalpindi|rawalpindi|pakistan` — added _(2026-05-12)_
- `locations.children´s hospital, karolinska university|stockholm||sweden` — added _(2026-05-12)_
- `locations.insel gruppe|bern||switzerland` — added _(2026-05-12)_
- `locations.hospital la rabta|tunis||tunisia` — added _(2026-05-12)_
- `locations.military hospital|tunis||tunisia` — added _(2026-05-12)_
- `locations.aydın adnan menderes university hospital|aydin|efeler|turkey (türkiye)` — added _(2026-05-12)_
- `locations.eskişehir osmangazi university hospital|eskişehir|eskişehir|turkey (türkiye)` — added _(2026-05-12)_
- `locations.çukurova university hospital|adana|sarıçam|turkey (türkiye)` — added _(2026-05-12)_
- `locations.dicle university hospital|diyarbakır|sur|turkey (türkiye)` — added _(2026-05-12)_
- `locations.royal brompton & harefield hospitals|london|london|united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05264753.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05264753*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*